Navigation Links
WorldHeart Signs Agreements for Next-Generation Minimally Invasive Blood Pump
Date:11/17/2009

SALT LAKE CITY, Nov. 17 /PRNewswire-FirstCall/ -- ("WorldHeart"; Nasdaq: WHRT) - World Heart Corporation (WorldHeart) announced today that it has finalized assignment and exclusive license agreements with LaunchPoint Technologies Inc., (LPT) Goleta, California, and Carnegie Mellon University (CMU), Pittsburgh, Pennsylvania for its next-generation minimally invasive blood pump, the MiVAD. The MiVAD(TM) is designed to provide partial cardiac support between 2-4 liters per minute to less sick heart failure patients than those served by existing full-support Left Ventricular Assist Devices (LVADs).

The MiVAD design is based on the Pediaflow(TM) LVAD design and intellectual property. The PediaFlow LVAD, a miniaturized implantable fully magnetically levitated blood pump, is intended for neonates and has evolved significantly through design and development. The latest version of the PediaFlow pump is approximately the size of a AA battery and was successfully evaluated in a multi-month animal trial this summer. The Pediaflow LVAD development has been led by the University of Pittsburgh, Pittsburgh, Pennsylvania and has been primarily funded by the National Heart, Lung and Blood Institute with supplemental funding and technology contributions from WorldHeart. WorldHeart, CMU and LPT are members of the development consortium. The work completed on this device is the foundation for the MiVAD. Additionally, the MiVAD will incorporate existing intellectual property as well as internal and external design features from the Levacor(TM) LVAD.

Mr. Alex Martin, WorldHeart's CEO, commented that, "while WorldHeart continues to focus on the clinical use and commercialization of the Levacor LVAD, these agreements allow WorldHeart to accelerate the development of the MiVAD and related technology in the area of miniaturization of magnetically levitated blood pumps".

Dr. Brad Paden, founder and CEO of LPT added that, "we are pleased that this breakthrough miniaturization technology will be integrated with WorldHeart's existing and complementary fully magnetically levitated blood pump platform to meet a new, large and promising clinical need".

About World Heart Corporation

WorldHeart is a developer of mechanical circulatory support systems in Salt Lake City, Utah with additional facilities in Oakland, California, USA and Herkenbosch, The Netherlands. WorldHeart's registered office is in Ottawa, Ontario, Canada.

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include all statements relating to the advancement of WorldHeart's clinical development programs, the potential clinical benefits of the Levacor LVAD, PediaFlow LVAD and MiVAD, and the growth of WorldHeart's overall business, as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: WorldHeart's need for additional capital in the future; risks in product development, regulatory approvals and market acceptance of and demand for WorldHeart's products; acquisition and commercialization of new technologies in the area of miniaturization of magnetically levitated blood pumps and successful development of the MiVAD; and other risks detailed in WorldHeart's filings with the U.S. Securities and Exchange Commission, including without limitation its Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2009, June 30, 2009 and September 30, 2009.

www.worldheart.com

SOURCE World Heart Corporation


'/>"/>
SOURCE World Heart Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
2. WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD
3. WorldHeart Receives IRB Approval at First Center in the Levacor(TM) VAD BTT Clinical Trial
4. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
5. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
6. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
7. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
8. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
9. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
10. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
11. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... N.Y. , May 22, 2017  Lilac ... treatment Gene-Eden-VIR/Novirin, announces the launch of a ... English, the results of a clinical study that ... year treatment with Gene-Eden-VIR/Novirin in individuals suffering from ... to note that there are no other treatments ...
(Date:5/15/2017)... , May 15, 2017  Amy Baxter MD, ... industry leader in noninvasive pain relief, was awarded a ... magazine. Baxter was recognized at the MM&M Top ... New York City on May 10, 2017. ... the biopharma industry go "beyond the pill."  ...
(Date:5/10/2017)... May 10, 2017 Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended April 1, 2017 ... $1.84 increased 666.7% compared to the prior year period ... in a significant gain, while non-GAAP diluted EPS of ... or 3.8% in constant currency terms.  Excluding the effects ...
Breaking Medicine Technology:
(Date:5/27/2017)... ... 27, 2017 , ... From May 21-23, hearing healthcare professionals gained a competitive ... at the Marriott Syracuse Downtown Hotel in Syracuse, New York. , As EarQ’s ... hearing healthcare providers to help them stay ahead in the industry. At the event, ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from biotech, ... 30th and 31st at The Four Seasons Hotel Boston. , The Boston ... sciences, offering exclusive access to key decision makers who influence deal making and ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of ... the healthiest seniors are located in the Midwest. With the average cost of healthcare ... people are concerned with both the quality and affordability of where they live. An ...
(Date:5/26/2017)... ... ... After raising nearly $30,000 on Kickstarter , about three-times its original ... discounted crowdfunding price on Indiegogo . , “Along with creating an anti-stress gadget ... a fidget toy to the market that was made of superior quality and wouldn’t ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled ... a new, informational blog post on insurance options. If a Bay Area patient has ... help save time and money. Visiting an in-network provider for a second opinion can ...
Breaking Medicine News(10 mins):